Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial

4 de junho de 2020

Lilia Gutierrez 1
, Graciela Tapia 2
, Luis Ocampo 1
, Minerva Monroy-Barreto 3 and
Hector Sumano 1,*
1 Departamento de Fisiología y Farmacologia, Facultad de Medicina Veterinaria y Zootecnia,
Universidad Nacional Autónoma de México, Avenida Universidad 3000, Coyoacan,
Mexico City 04510, Mexico; [email protected] (L.G.); [email protected] (L.O.)
2 Departamento de Genética y Bioestadística, Facultad de Medicina Veterinaria y Zootecnia,
Universidad Nacional Autónoma de México, Avenida Universidad 3000, Coyoacan,
Mexico City 04510, Mexico; [email protected]
3 Departamento de Química Analítica, Facultad de Química, Universidad Nacional Autónoma de México,
Avenida Universidad 3000, Coyoacan, Mexico City 04510, Mexico; [email protected]
* Correspondence: [email protected]; Tel.: +52-5556-225-908 (ext. 104)
Received: 23 March 2020; Accepted: 25 May 2020; Published: 29 May 2020


Simple Summary: This is the first report on the clinical use of a new derivative of enrofloxacin
(enrofloxacin HCl-2H2O or enro-C) for the treatment of canine unresponsive deep-pyoderma (UDCP),
utilizing a dual scheme, i.e., 10 mg/kg/day in capsules, plus the topical administration of enro-C, prepared
as an 0.5% alginate gel, thrice per day. Fifty-five cases of UDCP were treated successfully in a one-year
study. Mean days of treatment were 8 to 12, for either severe or very severe cases, respectively. Complete
success was recorded and no recurrences after a two-month clinical follow up were registered. It is here
proposed that the dual treatment, the potency of enro-C and the theoretically high concentrations of
the active principle in the lesions may explain these findings. Further research is needed to define the
bacteriological status of the pathogens found, and the impact of this treatment in bacterial resistance.
Abstract: An outpatient clinical trial on unresponsive deep-bacterial canine pyoderma (UDCP),
without a control group, is presented. The chosen treatment was implemented with a new
crystal-solvate of enrofloxacin (enrofloxacin HCl-2H2O or enro-C), in a dual scheme, i.e., 10 mg/kg/day
PO, plus its topical administration, prepared as 0.5% in an alginate gel, thrice per day. Fifty-five
cases that were unsuccessfully treated previously with another antibacterial drug, were selected
and then classified as severe or very severe, according to a clinical score tailored for this trial.
Aerobic bacteriological cultures of skin lesions and antibacterial sensitivity tests, were performed.
Hematological status, liver, and kidney functions were determined before and after treatment.
A complete success was obtained in 32 severe and 23 very severe, cases. The main bacterial isolates were:
Staphylococcus intermedius (19/99), Staphylococcus pseudintermedius (16/99), Staphylococcus epidermidis
(15/99), Staphylococcus pyogenes (14/99), Staphylococcus saprophyticus, Streptococcus sp., and others
including Pseudomonas aeruginosa (6/99). The average duration of treatment was 8.03 days ± 2.1 SD
and 12.0 ± 2.4 days, for dogs with severe or very severe UDCP, respectively. The adverse effects caused
by enro-C were inconsequential and the hematological tests showed no deviations from normality.
The use of enro-C administered dually to treat UDCP, is considered safe and highly effective.
Keywords: unresponsive canine deep-pyoderma; enrofloxacin hydrochloride-dihydrate; treatment;
clinical trial

Piodermite profunda, não responsiva, canino, cães, cão, enrofloxacina, tratamento

Comentar este artigo

Você precisa estar logado para comentar os artigos.
Desenvolvido por logo-crowd